NASDAQ: SCNIScinai Immunotherapeutics Ltd Stock
$2.15+0.10 (+4.88%)
Updated Apr 22, 2025
SCNI Price
$2.15
Fair Value Price
N/A
Market Cap
$0.00
52 Week Low
$1.90
52 Week High
$8.92
P/E
-0.09x
P/B
0x
P/S
6.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$452.00k
Earnings
-$4.70M
Gross Margin
-91.4%
Operating Margin
-1,038.94%
Profit Margin
-1,038.9%
Debt to Equity
0.23
Operating Cash Flow
-$6M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SCNI Overview
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCNI's potential to beat the market
- SCNI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SCNI
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.63 | A | |
| $7.89 | A | |
| $22.60 | A |
Be the first to know about important SCNI news, forecast changes, insider trades & much more!
SCNI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCNI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCNI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCNI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SCNI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SCNI due diligence checks available for Premium users.
Valuation
SCNI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
-208.37x
Market
28.14x
SCNI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
4.16x
SCNI's financial health
Profit margin
Revenue
$168.0k
Net Income
$10.5M
Profit Margin
6,223.2%
SCNI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SCNI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.3M
Liabilities
$2.3M
Debt to equity
0.23
SCNI's short-term assets ($1.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCNI's short-term assets ($1.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCNI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SCNI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$4.0k
Financing
$8.0k
SCNI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SCNI vs Biotech Stocks
Scinai Immunotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.